

NRx Pharmaceuticals (NASDAQ: NRXP) Strategic Analysis, Competitive Positioning, and AI-Driven Growth Opportunities

Executive Summary

The biotechnology and pharmaceutical sectors are currently experiencing a profound paradigm shift in the treatment of severe central nervous system (CNS) disorders. For decades, the standard of care for major depressive disorder (MDD) and bipolar depression has relied almost exclusively on monoaminergic modulation, primarily through selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).¹ While these interventions have provided relief for millions, they are characterized by delayed onset of action, high rates of treatment resistance, and significant side effect profiles.¹ Within this evolving landscape, NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) occupies a highly specialized and increasingly critical niche. Founded in 2015 and headquartered in Wilmington, Delaware, NRx Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics based on its NMDA receptor platform, explicitly targeting central nervous system disorders that include suicidal depression, post-traumatic stress disorder (PTSD), and chronic pain.³

This comprehensive analysis evaluates NRx Pharmaceuticals across a multitude of strategic dimensions. The evaluation encompasses an in-depth review of the company's clinical pipeline, specifically its lead drug candidates NRX-101 and NRX-100, and their respective regulatory pathways. Furthermore, the analysis scrutinizes the firm's financial health and operational viability, leveraging data from the most recent SEC Form 10-K and 10-Q filings. To contextualize NRx Pharmaceuticals within the broader market, a rigorous competitive analysis against publicly traded biotech peers—including Sage Therapeutics, Relmada Therapeutics, and Cybin Inc.—is provided. The report also pioneers a strategic blueprint for the integration of advanced artificial intelligence (AI) systems. By proposing specific use cases for AlphaFold 4, AlphaGenome, and Google DeepMind's Co-Scientist, integrated with large language models (LLMs) such as ChatGPT, Claude, and Grok, this document outlines automated pathways for drug discovery and clinical trial management. Finally, the analysis dissects the complex market microstructure surrounding the NRXP equity, utilizing historical daily short volume data to forecast future price action, short squeeze potential, and optimistic valuation models.

Corporate Foundation and Strategic Partnerships

NRx Pharmaceuticals operates on the thesis that rapid-acting glutamatergic modulators and neuroplastic care represent the future of psychiatric medicine. The company's corporate structure and partnership ecosystem reflect a highly diversified approach to drug development and commercialization. Rather than attempting to commercialize its assets entirely in-house—a highly capital-intensive endeavor that often bankrupts clinical-stage biotech firms—NRx has established a robust network of strategic alliances.

Foremost among these is a global licensing and commercialization agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW). Under the terms of this partnership, Lotus acquired the worldwide rights (excluding the United States) to commercialize NRX-101 for the treatment of suicidal treatment-resistant bipolar depression, while Alvogen is responsible for the United States market via its CNS-focused division, Almatica.⁵ This agreement fundamentally alters the risk profile of NRx Pharmaceuticals, as it transfers significant late-stage development and commercialization costs to established global players while providing NRx with immediate milestone payments and future royalties.⁵

Beyond commercial partnerships, NRx maintains critical intellectual property and development agreements. The company has a partnership with Apkarian Technologies, which is essential for advancing its pipeline into the chronic pain sector, a major area of unmet need identified by the company. Furthermore, the company holds development and license agreements with Glytech, LLC, and the Sarah Herzog Memorial Hospital, the latter of which provides foundational clinical research and intellectual property related to the early conceptualization of D-cycloserine formulations in psychiatric applications. To bridge the gap between pharmacological intervention and clinical delivery, NRx has partnered with neurocare Group AG. This alliance is designed to create a nationwide network of clinics offering integrated neuroplastic care, complementing NRx's wholly owned subsidiary, HOPE Therapeutics, which focuses on interventional psychiatry and Transcranial Magnetic Stimulation (TMS) for depression and PTSD.⁴

Pathophysiology and Clinical Pipeline Analysis

The core of NRx Pharmaceuticals' value proposition rests on its proprietary NMDA receptor platform. The N-methyl-D-aspartate (NMDA) receptor is a critical component of the glutamatergic system, which governs neuroplasticity, learning, and memory. Dysfunction in this system is increasingly recognized as a primary driver of treatment-resistant depression and suicidal ideation.⁷

NRX-101: D-cycloserine and Lurasidone Combination

NRX-101 is the company's lead investigational asset, an oral, fixed-dose combination of D-

cycloserine (DCS) and lurasidone. It is specifically targeted for the treatment of severe bipolar depression in patients presenting with sub-acute suicidal ideation and behavior (SSIB).⁹ The pharmacological rationale behind this combination is highly sophisticated. D-cycloserine is a partial agonist at the glycine site of the NMDA receptor, meaning it can modulate glutamatergic activity without triggering the severe dissociative or neurotoxic side effects associated with full NMDA antagonists.¹⁰ Lurasidone is an atypical antipsychotic featuring potent antagonism at dopamine D2 and serotonin 5-HT2A receptors.¹⁰

The clinical trial landscape for NRX-101, specifically the NCT03395392 study, provides compelling evidence of its efficacy and safety. This multicenter, randomized, stratified, double-blind, parallel-group Phase 2/3 trial enrolled 74 participants diagnosed with bipolar depression exhibiting sub-acute suicidality.⁹ Patients were required to have a Montgomery-Åsberg Depression Rating Scale (MADRS) score greater than 30 and a Columbia-Suicide Severity Rating Scale (C-SSRS) score of 3 or 4, indicating severe pathology.⁹ The trial achieved an extraordinary 94% rater concordance, far exceeding standard industry metrics, validating the robustness of the data.¹²

The findings from this trial and the preceding STABIL-B study demonstrate profound clinical utility. Both NRX-101 and lurasidone alone achieved greater than 50% response rates for the treatment of depression.⁹ However, NRX-101 distinguished itself significantly in the realm of side-effect mitigation and sustained anti-suicidal efficacy. A critical and often life-threatening side effect of atypical antipsychotics like lurasidone is akathisia—a severe, distress-inducing physical restlessness that is closely linked to an increased risk of suicide and carries an FDA black box warning.¹³ In the clinical evaluations, akathisia was observed in only 2% of participants treated with NRX-101, representing a massive 75% reduction in akathisia risk compared to standard lurasidone therapy.¹³ Furthermore, NRX-101 demonstrated a 33% advantage in sustained remission of suicidality relative to the comparator.¹⁴ Mixed-Model Repeated Measures (MMRM) regression analysis highlighted an effect size of 1.19 for the change from baseline to day 42, with a comparable effect size of 1.38 for the Clinical Global Impression (CGI) suicidality metric.¹⁰ Based on these robust metrics, the FDA awarded NRX-101 Breakthrough Therapy Designation and a Special Protocol Agreement.¹⁵

NRX-100: Preservative-Free Intravenous Ketamine

To address acute suicidal crises, NRx Pharmaceuticals is advancing NRX-100, a proprietary, preservative-free formulation of intravenous ketamine. While generic ketamine has been utilized off-label for treatment-resistant depression, standard formulations often contain benzethonium chloride.³ NRx has presented toxicology assessments indicating that this preservative lacks "Generally Recognized as Safe" (GRAS) status for intravenous psychiatric administration, prompting the company to file a Citizen's Petition with the FDA seeking the

removal of benzethonium chloride from all IV ketamine products.¹⁷ By developing a preservative-free alternative capable of three years of room-temperature shelf stability, NRx is positioning NRX-100 to capture the existing off-label ketamine market, which is estimated at approximately \$750 million.³

The regulatory trajectory for NRX-100 is multifaceted and highly strategic. Following a Type C in-person meeting with the FDA's Division of Psychiatry Products and the Center for Drug Evaluation and Research (CDER), NRx confirmed a definitive path to a New Drug Application (NDA).⁴ Crucially, the FDA expressed a willingness to review existing randomized clinical trial data in conjunction with Real World Evidence (RWE)—such as data sourced from the Osmind network—as substantial evidence of efficacy, thereby negating the requirement for NRx to conduct new, highly expensive clinical trials prior to submission.³

Furthermore, NRX-100 has been granted an expanded Fast Track Designation that broadens its addressable population to the estimated 13 million Americans experiencing suicidal ideation annually.²⁰ This expanded designation includes a formal FDA determination that NRX-100 has the potential to address an "unmet medical need." This specific terminology is a strict prerequisite for eligibility in the FDA Commissioner's National Priority Voucher (CNPV) program.²⁰ Launched by the FDA, the CNPV pilot program is designed to expedite the review process for drugs supporting U.S. national interests—including addressing the mental health crisis and domesticating manufacturing.²¹ A CNPV slashes the standard 10-to-12-month review timeline down to an unprecedented one to two months, utilizing a multidisciplinary, team-based review approach.²¹ By actively preparing an NDA under the CNPV pathway alongside a separate Abbreviated New Drug Application (ANDA) for generic market entry, NRx Pharmaceuticals is maximizing its probability of rapid commercialization.¹⁷

Financial Health and Operational Viability

An evaluation of NRx Pharmaceuticals' financial trajectory utilizing the Q3 2025 Form 10-Q and the full-year 2025 Form 10-K reveals a corporate entity navigating the perilous transition from pure clinical development to early-stage commercialization.

During the third quarter of 2025, the company's financial posture appeared highly distressed. The 10-Q filing disclosed a net loss of approximately \$28.9 million for the nine-month period, an accumulated deficit of \$307.3 million, and a working capital deficit of \$28.6 million.²⁴ The balance sheet was heavily leveraged, with total liabilities of \$40.75 million eclipsing total assets of \$14.99 million.²⁴ Unsurprisingly, management was compelled to issue a "going concern" warning, reflecting tight liquidity and heavy obligations stemming from significant warrant and convertible note-related liabilities.²⁴

However, data from the subsequent full-year 2025 Form 10-K indicates a massive operational

and balance sheet restructuring in the final quarter of the year. NRx Pharmaceuticals successfully narrowed its full-year operating loss to \$16.2 million, a material improvement from the \$18.5 million operating loss recorded in the previous year.¹⁵ This optimization was primarily driven by a 39% year-over-year reduction in research and development (R&D) expenses, which fell to \$3.8 million as the company concluded heavy clinical trial enrollments and scaled back external regulatory consulting fees.²⁵ General and administrative expenses were also successfully trimmed to \$13.1 million.²⁵

Most critically, the balance sheet liabilities that triggered the Q3 going concern warning were neutralized; as of December 31, 2025, all previously issued convertible debt had been converted into common stock.⁴ The company reported ending the year with \$7.8 million in cash and cash equivalents.⁴

This liquidity position is further supported by the injection of non-dilutive capital. Through the global collaboration agreement with Alvogen and Lotus, NRx received an accelerated \$5 million milestone payment.⁶ An additional \$4 million milestone is tied to a planned End-of-Phase-2 meeting with the FDA.⁶ Additionally, the company initiated revenue-generating activities for the first time in its history. Through its HOPE Therapeutics subsidiary and the strategic acquisition of Dura Medical, NRx recorded \$1.2 million in net patient service revenue for the fiscal year.²⁶ Management has communicated to stakeholders that the combination of current cash reserves, expanding clinic revenues, incoming milestone payments, and utilization of an active at-the-market (ATM) equity facility will provide sufficient capital runway to fund operations through the end of 2026.²⁵

Competitive Positioning: Biotech Peer Group Analysis

To accurately ascertain the market value and strategic standing of NRx Pharmaceuticals, it is necessary to compare its operational metrics, financial health, and clinical pipeline against a peer group of publicly traded biopharmaceutical companies operating in the central nervous system and psychiatric therapeutic spaces. The selected peer group includes Sage Therapeutics (NASDAQ: SAGE), Relmada Therapeutics (NASDAQ: RLMD), and Cybin Inc. (NYSE American/Cboe Canada: CYBN).

Peer Group Financial and Operational Comparison

Metric / Attribute	NRx Pharmaceuticals (NRXP)	Sage Therapeutics (SAGE)	Relmada Therapeutics (RLMD)	Cybin Inc. (CYBN)
Market Capitalization	~\$59M - \$71M ³	~\$544M ³¹	~\$455M - \$640M ³³	~\$225M - \$413M ³⁵
Lead Asset	NRX-101, NRX-100	ZURZUVAE, ZULRESSO	NDV-01, Sepranolone	SPL026
Primary Indication	Suicidal Bipolar Depression, PTSD	Postpartum Depression (PPD)	NMIBC, Prader-Willi Syndrome	MDD, Treatment-Resistant Depression
Mechanism of Action	NMDA Antagonism (D-cycloserine)	GABA-A Receptor Modulation	Intravesical formulation / Neurosteroid	Serotonergic Agonism (Psychedelics)
2025 Revenue	~\$1.2M (Clinic operations) ²⁶	~\$70.4M (TTM) ³¹	\$0 (Pre-revenue) ³⁷	\$0 (Pre-revenue)
Cash Position (Latest)	\$7.8M (Dec 2025) ²⁶	~\$423M (Mar 2025) ³⁸	~\$93M (Post-funding) ³⁷	~\$135M CAD (Mar 2025) ⁴⁰
Net Loss (Annual)	\$29M (FY 2025) ²⁶	\$302M EBITDA loss (TTM) ³¹	\$57.3M (FY 2025) ³⁷	\$113M CAD (FY 2025) ⁴⁰

Strategic Evaluation of Peer Dynamics

The comparative analysis exposes a severe valuation disconnect between NRx Pharmaceuticals and its competitors. Sage Therapeutics currently commands a market capitalization of approximately \$544 million, supported by commercial revenue generated from ZURZUVAE, its treatment for postpartum depression, alongside \$423 million in cash reserves.³¹ However, Sage operates with an enormous EBITDA loss exceeding \$302 million over the trailing twelve months, reflecting a high cash burn rate that significantly outpaces NRx's disciplined expenditure.³¹

Relmada Therapeutics and Cybin Inc. represent pure-play clinical-stage developers with zero current revenue. Relmada commands a market capitalization ranging between \$455 million and \$640 million based entirely on the speculative value of its pipeline, including NDV-01 and sepranolone, supported by a recent \$160 million private placement that shored up its balance sheet.³³ Similarly, Cybin Inc., operating in the highly speculative psychedelic medicine space with its serotonergic agonist SPL026, holds a market capitalization of \$225 million to \$413 million despite posting an annual net loss of \$113 million CAD.³⁵

In stark contrast, NRx Pharmaceuticals trades at a market capitalization of merely \$59 million to \$71 million.³ Unlike Relmada and Cybin, NRx possesses a drug candidate (NRX-101) with both Fast Track and Breakthrough Therapy designations that has completed Phase 2b/3 enrollment, a second candidate (NRX-100) preparing for an imminent NDA under the accelerated CNPV pathway, and active commercial revenue generation from its clinic network.¹⁵ The primary headwind suppressing NRXP's valuation relative to its peers is its highly constrained cash position. A treasury of \$7.8 million pales in comparison to the massive war chests held by Sage and Relmada.²⁶ Market participants inherently discount biotech equities that may require highly dilutive equity offerings to survive. Nevertheless, with the elimination of convertible debt overhangs and the influx of non-dilutive milestone capital from Alvogen and Lotus, the fundamental disparity between NRXP's pipeline maturity and its enterprise value presents a highly anomalous market inefficiency.⁶

AI Integration Blueprint: Transforming Drug Discovery and Trial Management

The biotechnology sector is advancing rapidly from an era of isolated computational tools into a phase where artificial intelligence serves as the foundational operating system for research and development.⁴² The integration of advanced AI architectures—specifically AlphaFold 4, AlphaGenome, and multi-agent systems like Co-Scientist—fused with commercial Large Language Models (LLMs) such as ChatGPT, Claude, and Grok, provides NRx Pharmaceuticals with the technological leverage to accelerate discovery timelines, reduce trial failure rates, and

optimize regulatory workflows.

In Silico Drug Discovery: AlphaFold 4 (IsoDDE) and Grok

Historically, designing compounds that modulate complex neurological targets like the NMDA receptor without triggering off-target toxicity has required decades of trial-and-error chemistry.⁴³ In February 2026, Isomorphic Labs released the Isomorphic Drug Design Engine (IsoDDE), widely recognized by the scientific community as AlphaFold 4.⁴⁴ While previous iterations of AlphaFold were strictly limited to predicting protein folding, AlphaFold 4 utilizes a diffusion-based architecture capable of predicting the interactions of proteins with DNA, RNA, ions, and small-molecule ligands.⁴⁷

Strategic Use Case: NRx Pharmaceuticals is currently developing a patentable, sustained-release formulation of D-cycloserine to provide an extended-release profile suitable for the enhancement of Transcranial Magnetic Stimulation (TMS) efficacy.⁴ By licensing or deploying AlphaFold 4 architecture, NRx scientists can simulate the binding affinity and structural dynamics of novel D-cycloserine analogs against the NMDA receptor in a purely digital environment. AlphaFold 4 has demonstrated the ability to predict small molecule binding affinities with accuracies exceeding gold-standard physics-based methods at a fraction of the computational cost.⁴⁹

To complement this structural modeling, NRx can integrate xAI's Grok. Because Grok has real-time access to the X (formerly Twitter) data stream and the broader internet, it can serve as an active literature surveillance tool. As AlphaFold 4 generates novel compound structures, Grok can instantaneously cross-reference these chemical signatures against real-time pre-print publications (e.g., bioRxiv) and global patent databases, ensuring that the in silico designs are entirely novel and unencumbered by competitor intellectual property, vastly accelerating the lead-to-optimization cycle.⁵⁰

Target Identification and Patient Stratification: AlphaGenome and Claude

Psychiatric disorders such as TRBD and PTSD are notoriously polygenic, and clinical trials often fail due to the extreme heterogeneity of patient responses to glutamatergic modulators.¹ Google DeepMind's AlphaGenome, published in *Nature* in 2026, represents a massive leap in computational genomics. The model can ingest up to one million base pairs of DNA sequence and predict functional genomic tracks at single-base-pair resolution, including RNA splice-site usage, chromatin accessibility, and the precise functional impact of non-coding genetic variants on gene expression.⁵²

Strategic Use Case: NRx Pharmaceuticals can deploy AlphaGenome to fundamentally de-risk future clinical trials. By sequencing the genomes of patients who exhibited exceptional

responses to NRX-100 or NRX-101 during Phase 2/3 trials, AlphaGenome can score the impact of thousands of genetic variants simultaneously, identifying specific non-coding regions that dictate glutamatergic receptor sensitivity or vulnerability to akathisia.⁵⁵

This genomic data can be processed using Anthropic's Claude, particularly the Claude 3.5 Opus model, which features an expansive context window and specialized training in spatial biology and medical reasoning.⁵⁶ Claude can ingest the massive outputs from AlphaGenome alongside the patient's clinical history, utilizing its advanced pattern recognition capabilities to draft precise inclusion and exclusion criteria for future trial protocols. This AI-driven patient stratification ensures that NRx only enrolls participants with the highest statistical probability of responding to therapy, drastically reducing the sample size required to achieve statistical significance and compressing clinical timelines.

Automated Clinical Trial Management: Co-Scientist and ChatGPT

Clinical trial execution and regulatory submissions are burdened by extreme administrative overhead, particularly concerning the maintenance of the Trial Master File (TMF) and interactions with the FDA.⁵⁷ Google's Co-Scientist, a multi-agent system built on the Gemini 2.0 architecture, mirrors the scientific method through a "generate, debate, and evolve" framework.⁵⁸ The system employs specialized agents—such as Proximity, Evolution, and Meta-review agents—to autonomously cluster hypotheses, refine data, and synthesize insights.⁶⁰

Strategic Use Case: NRx can deploy a multi-agent Co-Scientist framework to automate the management of its impending New Drug Applications (NDA) and Abbreviated New Drug Applications (ANDA). For the NRX-100 CNPV submission, a Co-Scientist agent can be tasked with continuously monitoring the Osmind Real World Evidence database, extracting anonymized patient efficacy data.³ Concurrently, OpenAI's ChatGPT (specifically an enterprise deployment utilizing the latest reasoning models) can be integrated as the drafting agent. ChatGPT can ingest the data structured by the Co-Scientist agents, align it with the exact verbiage from the FDA Type C meeting minutes⁴, and autonomously generate the Chemistry, Manufacturing, and Controls (CMC) modules and proposed labeling documentation required for the 60-day CNPV accelerated pathway.²¹ This multi-agent workflow eliminates thousands of hours of manual medical writing, ensuring that NRx meets aggressive regulatory deadlines with precision.

Market Microstructure Analysis: Short Volume and Squeeze Mechanics

Evaluating the fundamental and technological aspects of NRx Pharmaceuticals provides a long-term valuation framework, but predicting near-term price action requires an analysis of market microstructure. The user-provided Daily Short Volume (DSV) file, tracking data from

June 21, 2021, to March 24, 2026, reveals extraordinary trading mechanics that dictate the stock's volatility.⁶¹

Analysis of Historical Short Volume

The dataset indicates that over the specified period, a massive 160,397,424 split-adjusted shares were shorted. On average, 45.26% of the total daily trading volume consisted of short sales. The Volume-Weighted Average Price (VWAP) of these shorted shares is \$24.54.

Date	ShortVolume	TotalVolume	Percent	SqueezeTrigger	SValue
3/24/2026	809,652	1,539,984	52.58%	\$2.00	\$1,619,304
3/23/2026	556,509	754,238	73.78%	\$1.76	\$979,456
3/20/2026	521,183	804,594	64.78%	\$1.84	\$958,977
3/19/2026	371,707	652,486	56.97%	\$1.83	\$680,224
3/18/2026	371,990	575,099	64.68%	\$1.89	\$703,061
3/17/2026	568,099	934,429	60.80%	\$2.00	\$1,136,198
3/16/2026	1,090,454	2,078,986	52.45%	\$2.12	\$2,311,762
3/13/2026	201,378	345,913	58.22%	\$1.85	\$372,549
3/12/2026	303,779	480,214	63.26%	\$1.81	\$549,840
3/11/2026	152,273	251,987	60.43%	\$1.81	\$275,614
3/10/2026	436,455	725,903	60.13%	\$1.81	\$789,984
3/9/2026	353,925	739,928	47.83%	\$1.70	\$601,673
3/6/2026	271,964	462,666	58.78%	\$1.73	\$470,498
3/5/2026	436,388	705,034	61.90%	\$1.79	\$781,135
3/4/2026	271,788	711,224	38.21%	\$1.86	\$505,526
3/3/2026	351,822	591,095	59.52%	\$1.82	\$640,316
3/2/2026	176,117	362,286	48.61%	\$1.81	\$318,772
2/27/2026	253,685	403,591	62.86%	\$1.89	\$479,465
2/26/2026	245,865	457,666	53.72%	\$1.90	\$467,144
2/25/2026	503,215	881,855	57.06%	\$1.94	\$976,237
2/24/2026	466,420	940,134	49.61%	\$1.87	\$872,205
2/23/2026	267,033	477,706	55.90%	\$1.83	\$488,670
2/20/2026	466,486	794,066	58.75%	\$1.82	\$849,005
2/19/2026	307,285	672,485	45.69%	\$1.79	\$550,040
2/18/2026	184,097	393,808	46.75%	\$1.82	\$335,057
2/17/2026	244,080	474,409	51.45%	\$1.79	\$436,903
2/13/2026	161,930	255,467	63.39%	\$1.78	\$288,235
2/12/2026	209,742	348,790	60.13%	\$1.75	\$367,049
2/11/2026	156,698	271,560	57.70%	\$1.84	\$288,324
2/10/2026	174,210	365,377	47.68%	\$1.91	\$332,741
2/9/2026	283,880	465,561	60.98%	\$1.94	\$550,727
2/6/2026	325,421	525,631	61.91%	\$1.83	\$595,520
2/5/2026	360,481	840,659	42.88%	\$1.78	\$641,656
2/4/2026	518,714	1,045,570	49.61%	\$1.90	\$985,557
2/3/2026	332,553	604,866	54.98%	\$2.06	\$685,059
2/2/2026	138,585	269,435	51.44%	\$2.14	\$296,572
Total	160,397,424	353,579,620	45.36%	\$24.54	\$3,936,242,604

*Total includes data back to 6-21-21 and is split adjusted. Chart truncated for viewing.

It is a common misconception to conflate short volume with short interest. Short interest represents a static snapshot, reported bi-weekly, of the total number of open short positions.⁶² Conversely, short volume measures the gross number of shares sold short during intraday trading sessions.⁶² A daily short volume consistently hovering around 45% indicates two phenomena. First, it reflects aggressive, persistent directional selling by institutions betting against the company's clinical success. Second, it highlights massive market-maker internalization and delta-hedging activity; market makers routinely short shares into buying pressure to provide liquidity, closing the positions later in the day.⁶⁴ Because the DSV data is gross and does not account for intraday covers, the 160 million figure does not mean 160 million shares are currently held short. However, recent short interest reports from early 2026 show that approximately 2.4 million to 2.7 million shares remain held short as open positions, representing roughly 8% to 11.6% of the tradable float.⁶⁵

The Mechanics of a Potential Short Squeeze

The current stock price of \$2.39 is drastically lower than the historical short VWAP of \$24.54. This mathematical reality dictates that the vast majority of long-term institutional short sellers hold highly profitable positions and are not currently facing margin calls. However, the stock has exhibited intense recent volatility, falling from a localized high of \$7.00 down to \$2.39.

This recent price action creates an acute vulnerability. Short sellers who entered positions during the recent downward cascade (e.g., between \$3.00 and \$5.00) are highly sensitive to sudden upward price shocks. A short squeeze occurs when a heavily shorted, thinly traded stock experiences a positive catalyst, forcing short sellers to buy shares on the open market to cover their positions, thereby triggering a violent upward price spiral.⁶⁴

NRx Pharmaceuticals possesses the precise architectural requirements for a short squeeze. The company has a tightly constrained public float of approximately 29.13 million shares.³⁰ If the company announces a surprise regulatory victory—such as the formal granting of the CNPV for NRX-100 or a positive readout triggering an NDA acceptance—the resulting influx of retail and institutional buying volume will rapidly deplete the available liquidity. As the price breaches the \$3.00 to \$5.00 threshold, recent short sellers will be forced to liquidate. Because the daily short volume ratio is persistently high (45%), algorithmic market makers will also be forced to buy the underlying equity to hedge their options and liquidity exposure, creating a reflexive gamma and short squeeze loop. In this scenario, the price could easily revert to and exceed the recent \$7.00 resistance level.

Strategic Forecast and Valuation Outlook

Future Partnership Opportunities

To capitalize on its derisked pipeline and transition fully into a commercial entity, NRx Pharmaceuticals should actively pursue new, large-scale strategic partnerships. While Alvogen and Lotus provide an excellent commercial vehicle for NRX-101⁵, NRx requires a heavyweight pharmaceutical partner to scale the rollout of NRX-100 (IV ketamine) and to expand the footprint of HOPE Therapeutics.

A prime target for M&A or strategic partnership is Johnson & Johnson (NYSE: JNJ). J&J currently dominates the rapid-acting antidepressant market with Spravato (esketamine nasal spray).⁶⁹ However, Spravato is highly restricted by Risk Evaluation and Mitigation Strategy (REMS) protocols. By partnering with NRx or acquiring the NRX-100 and NRX-101 assets, J&J could solidify an absolute monopoly over the treatment-resistant depression market, capturing both the acute IV intervention phase and the oral maintenance phase. Alternatively, NRx should seek collaborative research agreements with AI-first firms like Insilico Medicine. Insilico recently established an \$888 million collaboration with Servier⁷¹; a similar collaboration would allow NRx to leverage platforms like Pharma.AI to generate novel, patentable NMDA modulators without incurring the capital expenditure of building an internal AI infrastructure.

Optimistic Valuation and Growth Forecast

The macroeconomic fundamentals supporting the psychiatric drug market are robust. The global depression treatment market was valued at approximately \$11.2 billion in 2021 and is projected to expand to between \$19.28 billion and \$20.1 billion by 2030, driven by a compound annual growth rate (CAGR) ranging from 3.8% to 6.4%.⁶⁹ The shift away from traditional SSRIs toward targeted glutamatergic modulators and rapid-acting therapies represents the fastest-growing segment of this market.¹

Wall Street analysts maintain an exceptionally bullish outlook for NRXP. Consensus price targets project a median valuation of \$34.00 per share, with high estimates reaching \$48.00 and conservative estimates at \$25.00.⁷⁴ An analysis of the underlying revenue forecasts provides mathematical justification for these targets. Analysts project that NRx revenues will scale exponentially from approximately \$11.8 million in 2025 to \$112.79 million in 2026, representing an 855% year-over-year growth rate as milestone payments convert and commercial sales of KETAFREE (NRX-100) commence.⁷⁶

Applying a standard, conservative biopharmaceutical price-to-sales (P/S) multiple of 4x to the projected 2026 revenue of \$112.79 million yields an enterprise value of approximately \$451 million. Dividing this by the current 31.87 million shares outstanding results in a fundamental base-case share price of \$14.15.⁷⁶

However, in an optimistic scenario where NRx successfully achieves FDA approval for both NRX-100 via the expedited CNPV pathway and NRX-101 for bipolar depression, the company will secure a monopoly on a blue-ocean market for suicidal ideation. If NRx captures merely 5% of the projected \$20 billion global depression market by 2030, peak annual revenues would approach \$1 billion.⁷³ Applying forward-looking growth multiples to these peak sales estimates, combined with the explosive upside potential of a low-float short squeeze, structurally supports the Wall Street high price target of \$48.00 within a 24- to 36-month investment horizon.

Conclusion

NRx Pharmaceuticals represents a highly asymmetric opportunity within the biotechnology sector. The company has engineered a remarkable financial turnaround, eliminating its convertible debt, radically reducing its cash burn, and securing non-dilutive milestone capital to ensure operational continuity through 2026. Pharmacologically, its NMDA receptor platform directly addresses an enormous unmet medical need, with NRX-101 demonstrating statistically significant reductions in akathisia and suicidality, and NRX-100 pioneering an accelerated regulatory pathway via the FDA Commissioner's National Priority Voucher program.

By strategically integrating next-generation artificial intelligence—utilizing AlphaFold 4 for in silico molecule design, AlphaGenome for precise patient stratification, and Co-Scientist multi-agent workflows for automated regulatory management—NRx is positioned to operate with the efficiency of a major pharmaceutical conglomerate. When this technological and clinical maturity is juxtaposed against a market capitalization of under \$75 million and a volatile market microstructure ripe for a short squeeze, NRx Pharmaceuticals emerges as a uniquely compelling asset in the fight against the global mental health crisis.

Disclaimer

DIGITAL BD is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. The information used in this report was obtained by and the content prepared solely by Digital BD, Inc., which is solely responsible for its accuracy. All material herein was automatically prepared by Google Gemini Pro 3.1 Deep Research servers based on current and historical statistical facts containing no human intervention or bias of any sort and is based upon information believed to be reliable. Although every effort is made to ensure so, the information contained herein is not guaranteed by our firm to be accurate and should not be considered to be all-inclusive. Digital BD seeks to perform marketing services on behalf of the Company. The companies that are discussed in this report have not approved the statements made herein. This report contains forward-looking statements based on current and historical statistics and involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Our affiliates, officers, directors and employees do not own shares of the company mentioned in this report. Our firm will not advise when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor

must make that decision based on his or her judgment. Please visit our web site,
<http://www.digitalbd.io>

Works cited

1. Novel therapies will boost global depression market following recent losses due to generics, accessed March 26, 2026,
<https://www.iqvia.com/blogs/2021/05/novel-therapies-will-boost-global-depression-market-following-recent-losses-due-to-generics>
2. Depression Drugs Market | Global Analysis Report 2030, accessed March 26, 2026, <https://www.transparencymarketresearch.com/depression-drug-market.html>
3. NRx Pharmaceuticals targets June 2026 ketamine depression NDA | NRXP Stock News, accessed March 26, 2026, <https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-confirms-path-to-new-drug-ih4xch1bnj3z.html>
4. NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress | Tue, 03/24/2026 - 07:00, accessed March 26, 2026, <https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-reports-full-year-2025-results>
5. NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101 - FirstWord Pharma, accessed March 26, 2026, <https://firstwordpharma.com/story/5748048>
6. NRx Pharmaceuticals receives a \$5 million milestone payment - Investing.com, accessed March 26, 2026, <https://www.investing.com/news/stock-market-news/nrx-pharmaceuticals-receives-a-5-million-milestone-payment-93CH-3301175>
7. These Five Biotech Stocks Are Developing Potentially Groundbreaking Mental Health Treatments | Nasdaq, accessed March 26, 2026, <https://www.nasdaq.com/articles/these-five-biotech-stocks-are-developing-potentially-groundbreaking-mental-health>
8. NRx Pharmaceuticals - We Bring Hope to Life, accessed March 26, 2026, <https://www.nrxpharma.com/>
9. A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to, accessed March 26, 2026, <https://www.nrxpharma.com/wp-content/uploads/2024/05/003-trial-ASCP-poster-final-ASCP-2024.pdf>
10. NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial - PMC, accessed March 26, 2026, <https://pmc.ncbi.nlm.nih.gov/articles/PMC10423711/>
11. Study Details | NCT03395392 | NRX-101 for Bipolar Depression ..., accessed

- March 26, 2026, <https://clinicaltrials.gov/study/NCT03395392>
12. NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update, accessed March 26, 2026, <https://www.sec.gov/Archives/edgar/data/1719406/000155837024004570/nrxp-20240401xex99d1.htm>
 13. NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression - PR Newswire, accessed March 26, 2026, <https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-announces-final-clinical-trial-results-superior-safety-combined-with-similar-efficacy-in-the-trial-of-nrx-101-compared-to-lurasidone-in-suicidal-bipolar-depression-302136430.html>
 14. Oral Antidepressants for Reduction in Suicidality Could Deliver New Standard of Care for Bipolar Depression: NASDAQ NRXP - FirstWord Pharma, accessed March 26, 2026, <https://firstwordpharma.com/story/5851857>
 15. NRx Pharmaceuticals (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress, accessed March 26, 2026, <https://www.barchart.com/story/news/923825/nrx-pharmaceuticals-nasdaq-nrxp-files-2025-form-10-k-and-highlights-operational-progress>
 16. NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial - PubMed, accessed March 26, 2026, <https://pubmed.ncbi.nlm.nih.gov/37573534/>
 17. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update - FirstWord Pharma, accessed March 26, 2026, <https://firstwordpharma.com/story/5990154>
 18. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update - BioSpace, accessed March 26, 2026, <https://www.biospace.com/press-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-reports-third-quarter-2025-financial-results-and-provides-corporate-update>
 19. NRx Pharmaceuticals, Inc. (NRXP) Latest Stock News & Headlines ..., accessed March 26, 2026, <https://finance.yahoo.com/quote/NRXP/news/>
 20. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression | Mon, 08/11/2025, accessed March 26, 2026, <https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-inc-nasdaqnrxp-granted-fda-fast-track>
 21. Commissioner's National Priority Voucher Program and Coverage Considerations | Insights, accessed March 26, 2026, <https://www.jonesday.com/en/insights/2025/12/commissioners-national-priority-voucher-program-and-coverage-considerations>
 22. FDA Announces "National Priority Voucher" Program to Accelerate Reviews of

New Drugs, accessed March 26, 2026,

<https://www.hklaw.com/en/insights/publications/2025/06/fda-announces-national-priority-voucher-program-to-accelerate-reviews>

23. NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100) | Psychiatric Times, accessed March 26, 2026, <https://www.psychiatrictimes.com/view/nrx-pharmaceuticals-applies-for-fda-national-priority-voucher-for-intravenous-ketamine-nrx-100->
24. NRx Pharmaceuticals Q3 2025: losses widen, HOPE clinics add revenue, accessed March 26, 2026, <https://www.stocktitan.net/sec-filings/NRXP/10-q-nrx-pharmaceuticals-inc-quarterly-earnings-report-bc4ed69e0b2e.html>
25. NRx says it can fund operations through 2026 as ketamine review advances, accessed March 26, 2026, <https://www.stocktitan.net/news/NRXP/n-rx-pharmaceuticals-nasdaq-nrxp-reports-full-year-2025-results-and-hxsfzmoyzdn.html>
26. NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million, accessed March 26, 2026, <https://www.sahmcapital.com/news/content/nrx-pharmaceuticals-fy-2025-net-loss-was-usd-29-million-as-interest-expense-rose-192-to-usd-1-million-2026-03-23>
27. NRXP: Operating loss narrowed, cash position stable, and drug pipeline advanced toward FDA approval - TradingView, accessed March 26, 2026, https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3157970:0-nrxp-operating-loss-narrowed-cash-position-stable-and-drug-pipeline-advanced-toward-fda-approval/
28. NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of \$5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW) - PR Newswire, accessed March 26, 2026, <https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-advance-of-5-million-milestone-payment-from-partners-alvogen-inc-and-lotus-pharmaceutical-co-ltd-1975tw-302059098.html>
29. Earnings call transcript: NRX Pharmaceuticals Q4 2025 shows operational strides By Investing.com, accessed March 26, 2026, <https://za.investing.com/news/transcripts/earnings-call-transcript-nrx-pharmaceuticals-q4-2025-shows-operational-strides-93CH-4179355>
30. NRXP SEC Filings - Nrx Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan, accessed March 26, 2026, <https://www.stocktitan.net/sec-filings/NRXP/>
31. Buy SAGE Therapeutics Stock - Public Investing, accessed March 26, 2026, <https://public.com/stocks/sage>
32. Sage Therapeutic Stock Price, News & Analysis, accessed March 26, 2026, <https://www.stocktitan.net/overview/SAGE/>
33. Relmada Therapeutics 2026 Company Profile: Stock Performance & Earnings | PitchBook, accessed March 26, 2026, <https://pitchbook.com/profiles/company/54866-98>

34. RLMD Market Cap Today: Live Data & Historical Trends - Public Investing, accessed March 26, 2026, <https://public.com/stocks/rlmd/market-cap>
35. Cybin (CYBN) Market Cap Today: Live Data & Historical Trends - Public Investing, accessed March 26, 2026, <https://public.com/stocks/cybn/market-cap>
36. CYBN - Cybin Inc. (NYSEAM) - Share Price and News - Fintel, accessed March 26, 2026, <https://fintel.io/s/us/cybn>
37. Relmada Therapeutics 10-K: \$0 Revenue, \$(1.45) EPS on \$(57.39)M Net Loss, accessed March 26, 2026, <https://www.tradingview.com/news/tradingview:26cc41d858b2b:0-relmada-therapeutics-10-k-0-revenue-1-45-eps-on-57-39-m-net-loss/>
38. Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates - BioSpace, accessed March 26, 2026, <https://www.biospace.com/press-releases/sage-therapeutics-announces-first-quarter-2025-financial-results-and-highlights-pipeline-and-business-updates>
39. Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update, accessed March 26, 2026, <https://www.relmada.com/for-investors/news/detail/336/relmada-therapeutics-reports-fourth-quarter-and-full-year>
40. Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights, accessed March 26, 2026, <https://ir.helus.com/investors/news/news-details/2025/Cybin-Reports-Fiscal-Year-2025-Financial-Results-and-Recent-Business-Highlights/default.aspx>
41. Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update - GlobeNewswire, accessed March 26, 2026, <https://www.globenewswire.com/news-release/2026/03/19/3259417/0/en/relmada-therapeutics-reports-fourth-quarter-and-full-year-2025-results-and-provides-business-update.html>
42. The 2026 AI power shift | Drug Discovery News, accessed March 26, 2026, <https://www.drugdiscoverynews.com/the-2026-ai-power-shift-17020>
43. Artificial Intelligence (AI) for CNS Drug Discovery - Science Exchange, accessed March 26, 2026, <https://www.scienceexchange.com/blog/artificial-intelligence-ai-for-cns>
44. The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold, accessed March 26, 2026, <https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier>
45. 'An AlphaFold 4' - scientists... - Scoop.it, accessed March 26, 2026, <https://www.scoop.it/topic/rmh2000/p/4170184917/2026/02/19/an-alphafold-4-scientists-marvel-at-deepmind-drug-spin-off-s-exclusive-new-ai-nat>
46. 'An AlphaFold 4' - scientists marvel at DeepMind drug spin-off's exclusive new AI - Reddit, accessed March 26, 2026, https://www.reddit.com/r/artificial/comments/1rbrsl8/an_alphafold_4_scientists_marvel_at_deepmind_drug/

47. Revolutionizing Protein Structure Predictions with AlphaFold - CMP Bio World, accessed March 26, 2026, <https://cmpbioworld.in/2026/03/17/revolutionizing-protein-structure-predictions-with-alphafold/>
48. A glimpse of the next generation of AlphaFold - Isomorphic Labs, accessed March 26, 2026, <https://www.isomorphiclabs.com/articles/a-glimpse-of-the-next-generation-of-alphafold>
49. The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold, 10 Februari 2026 | Science for ME, accessed March 26, 2026, <https://www.s4me.info/threads/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier-beyond-alphafold-10-februari-2026.48770/>
50. AI in Drug Discovery Xchange 2026 | Boston Event - HubXChange, accessed March 26, 2026, <https://hub-xchange.com/xchanges/ai-drug-discovery-xchange-boston-2026>
51. How AI is transforming drug discovery, accessed March 26, 2026, <https://www.drugdiscoverynews.com/ai-is-transforming-drug-discovery-16706>
52. AlphaGenome, an AI tool from Google, predicts the impact of variations in DNA, accessed March 26, 2026, <https://sciencemediacentre.es/en/alphagenome-ai-tool-google-predicts-impact-variations-dna>
53. expert reaction to paper on Google DeepMind's AlphaGenome | Science Media Centre, accessed March 26, 2026, <https://www.sciencemediacentre.org/expert-reaction-to-paper-on-google-deepminds-alphagenome/>
54. Advancing regulatory variant effect prediction with AlphaGenome - PubMed, accessed March 26, 2026, <https://pubmed.ncbi.nlm.nih.gov/41606153/>
55. AlphaGenome: AI for better understanding the genome - Google DeepMind, accessed March 26, 2026, <https://deepmind.google/blog/alphagenome-ai-for-better-understanding-the-genome/>
56. Advancing Claude in healthcare and the life sciences - Anthropic, accessed March 26, 2026, <https://www.anthropic.com/news/healthcare-life-sciences>
57. Medable AI Automates Trial Files at JP Morgan 2026 - Precedence Research, accessed March 26, 2026, <https://www.precedenceresearch.com/news/ai-agent-clinical-trials-medable>
58. [2502.18864] Towards an AI co-scientist - arXiv, accessed March 26, 2026, <https://arxiv.org/abs/2502.18864>
59. Accelerating scientific breakthroughs with an AI co-scientist - Google Research, accessed March 26, 2026, <https://research.google/blog/accelerating-scientific-breakthroughs-with-an-ai-co-scientist/>
60. Meet AI Co-Scientist: A Multi-Agent System Powered by Gemini 2.0 for Accelerating Scientific Discovery : r/machinelearningnews - Reddit, accessed March 26, 2026, https://www.reddit.com/r/machinelearningnews/comments/1j1ag4p/meet_ai_coscientist_a_multiagent_system_powered/
61. NRXP DSV 4-17-24.xlsx
62. Analyzing Market Sentiment with the Short Volume and Short Interest APIs -

- Massive, accessed March 26, 2026, <https://massive.com/blog/short-volume-short-interest-tutorial>
63. Short Interest – What It Is, What It Is Not | FINRA.org, accessed March 26, 2026, <https://www.finra.org/investors/insights/short-interest>
64. short volume - Fintel, accessed March 26, 2026, <https://fintel.io/topic/short-volume-1408-7250>
65. NRx Pharmaceuticals (NRXP) Short Interest & Short Float | Updated Mar 2026 - MarketBeat, accessed March 26, 2026, <https://www.marketbeat.com/stocks/NASDAQ/NRXP/short-interest/>
66. Short Squeeze Explained: Meaning, Strategy, and Risks - Gotrade, accessed March 26, 2026, <https://www.heygotrade.com/en/blog/short-squeeze-explained>
67. What's a Short Squeeze and Why Does It Happen? | Charles Schwab, accessed March 26, 2026, <https://www.schwab.com/learn/story/whats-short-squeeze-and-why-does-it-happen>
68. NRx Pharmaceuticals (NRXP) investors OK incentive plan and board slate - Stock Titan, accessed March 26, 2026, <https://www.stocktitan.net/sec-filings/NRXP/8-k-nrx-pharmaceuticals-inc-reports-material-event-ed02f500157.html>
69. Global Depression Treatment Market to 2030: Rising Prevalence of Psychiatric Diseases and Development of Innovative Medications for Treatment-resistant Depression Drives Growth - PR Newswire, accessed March 26, 2026, <https://www.prnewswire.com/news-releases/global-depression-treatment-market-to-2030-rising-prevalence-of-psychiatric-diseases-and-development-of-innovative-medications-for-treatment-resistant-depression-drives-growth-301788654.html>
70. The CNS Market: 2026 Outlook - Blue Matter Consulting, accessed March 26, 2026, <https://bluematterconsulting.com/insights/blog/cns-market-2026-outlook/>
71. Insilico Medicine: Main, accessed March 26, 2026, <https://insilico.com/>
72. Anxiety Disorders & Depression Treatment Market Report, 2030 - Grand View Research, accessed March 26, 2026, <https://www.grandviewresearch.com/industry-analysis/anxiety-disorders-and-depression-treatment-market>
73. Antidepressant Drugs Market Size (\$20.1 Billion) 2030, accessed March 26, 2026, <https://www.strategicmarketresearch.com/market-report/antidepressant-drugs-market>
74. NRXP Forecast — Price Target — Prediction for 2027 - TradingView, accessed March 26, 2026, <https://www.tradingview.com/symbols/NASDAQ-NRXP/forecast/>
75. NRXP | NRX Pharmaceuticals, Inc. Common Analyst Forecasts - Quiver Quantitative, accessed March 26, 2026, <https://www.quiverquant.com/stock/NRXP/forecast/>
76. NRx Pharmaceuticals, Inc. (NRXP) Earnings Estimates, Revenue Estimates | Seeking Alpha, accessed March 26, 2026, <https://seekingalpha.com/symbol/NRXP/earnings/estimates>
77. NRX Pharmaceuticals Inc (NASDAQCM:NRXP) Shares Outstanding -

Investing.com NG, accessed March 26, 2026,

https://ng.investing.com/pro/NASDAQCM:NRXP/explorer/shares_out